Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zymeworks Inc. - Common Stock (NQ:ZYME)

25.10 -0.93 (-3.57%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about Zymeworks Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Zymeworks Announces Participation in Upcoming Conferences
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Stock Sees Surge In Retail Chatter After Royalty Pivot, Cancer Trial Win Sparks Target Price Hikes ↗
Strong new Phase 3 Ziihera data boosted confidence in upcoming regulatory milestones. 
Via Stocktwits
News headline image
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
5 Analysts Have This To Say About Zymeworks ↗
 
Via Benzinga
News headline image
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:NTLA),(NASDAQ:ZYME),(NYSE:ANVS) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Alphabet To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans ↗
Zymeworks rises after Ziihera shows significant PFS and OS benefits in a Phase 3 trial, supporting plans for regulatory filings and guideline submissions. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
The market is filled with gapping stocks in Monday's session. ↗
In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
News headline image
Mixed Signals Point to Cautious Open for U.S. Markets as Tech Shines Amidst Economic Data Delays
U.S. equity futures are signaling a mixed but largely cautious start to the trading day on November 17, 2025, with technology stocks once again taking the lead, while broader indices like the Dow Jones... 
Via MarketMinute
Topics Artificial Intelligence Economy Electric Vehicles
News headline image
Jazz, Zymeworks Catapult On Their 'Sweeping Success' In Gastric Cancer ↗
Shares of Jazz Pharmaceuticals and Zymeworks catapulted Monday on positive test results for a gastric cancer drug. 
Via Investor's Business Daily
News headline image
These stocks are moving in today's pre-market session ↗
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Inc (NASDAQ:ZYME) Shows Strong Technical and Fundamental Momentum ↗
Discover how Zymeworks (ZYME) combines strong technical trends with accelerating earnings and sales growth, making it a top high-growth stock candidate. 
Via Chartmill
News headline image
Zymeworks Inc (NASDAQ:ZYME) Reports Mixed Q3 2025 Results with Narrower Loss but Revenue Miss ↗
Zymeworks Q3 2025: Narrower-than-expected loss and strong cash position, though revenue missed estimates. Clinical pipeline advances with promising data. 
Via Chartmill
News headline image
Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Broadcom To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
This RPM International Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗
 
Via Benzinga
News headline image
Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer
From Zymeworks Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.